Need Help? Call : (310) 914-5007
Need Help? Call : (310) 914-5007
The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors concerning the Company’s possible violations of federal securities laws.
What Is The Investigation About?
On December 30, 2024, after market hours, Sangamo disclosed that Pfizer Inc. (“Pfizer”) had notified the Company of its termination of a partnership to develop a hemophilia A gene therapy product candidate.
On this news, Sangamo’s stock price fell $1.32, or 56.4%, to close at $1.02 per share on December 31, 2024, thereby injuring investors.
If you suffered a loss on your Sangamo Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.
© 2025 The Law Offices of Frank R. Cruz. A Professional Services Corporation.
Website Designed & Developed By ITIFFY Consultants.